ArticleIn vitro cellular & developmental biology. Animal2026
miR-135a-5p exerts tumor-suppressive effects in 769P renal carcinoma cells through the TFAP2A/KRT8 signaling axis.
Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HAX1 Promotes Hepatocellular Carcinoma Progression by Inhibiting Ferroptosis Through Modulation of Iron Homeostasis and the GSH/GPX4 Pathway.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The oncogenic roles of microRNAs have been extensively documented across various cancer types. In the present study, we aimed to investigate the functional impact of miR-135a-5p on the clear cell renal cell carcinoma (ccRCC) cell line 769P. Through weighted gene co-expression network analysis (WGCNA), we identified a significant association between miR-135a-5p and ccRCC progression. Furthermore, miR-135a-5p expression was downregulated in both ccRCC tissues and cell lines. Functional assays demonstrated that miR-135a-5p inhibits the progression of 769P cells. Mechanistically, miR-135a-5p directly binds to the 3' untranslated region (3'UTR) of TFAP2A, reducing its mRNA stability. In turn, TFAP2A binds to the promoter region of KRT8 and activates its transcription, thereby mediating the inhibitory effect of miR-135a-5p on 769P cell progression. In conclusion, our findings provide evidence that miR-135a-5p suppresses ccRCC progression in 769P cells through the TFAP2A/KRT8 axis, highlighting its potential as a therapeutic target for ccRCC.
Indexed as
Identifiers
42101726What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.